Who Paid My Doc
Armando Troche Olivieri
Family Medicine Coamo, PR Medical Doctor
NPI 1710062211 CMS profile 31813
Calle Segundo Bernier #3, 150 Street 21.4 Kilometer, Coamo, PR 00769
General payments
$185
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Armando Troche Olivieri of Coamo, PR is reported in the CMS Open Payments database as having received $185 across 6 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 42nd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $11 | 1 | |
| 2019 | General | $174 | 5 |
Beside peers
- Armando Troche Olivieri
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Armando Troche Olivieri were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Armando Troche Olivieri | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $174 | $150 | $41–$543 | $163 |
| 2020 | $11 | $120 | $32–$415 | $114 |
| 2021 | $0 | $137 | $35–$551 | $132 |
| 2022 | $0 | $137 | $37–$512 | $149 |
| 2023 | $0 | $149 | $42–$545 | $160 |
| 2024 | $0 | $156 | $44–$560 | $164 |
| 2025 | $0 | $155 | $45–$549 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 181 drugsPart D claims
12,341
Drug cost
$461,952
Branded share of claims
22.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Synthroid Levothyroxine Sodium | Brand | 601 | $47,270 | |
| Januvia Sitagliptin Phosphate | Brand | 43 | $40,440 | |
| Jardiance Empagliflozin | Brand | 24 | $26,572 | |
| Entresto Sacubitril/Valsartan | Brand | 31 | $25,704 | |
| Eliquis Apixaban | Brand | 39 | $22,087 | |
| Xarelto Rivaroxaban | Brand | 22 | $19,157 | |
| Janumet Sitagliptin Phos/Metformin Hcl | Brand | 13 | $14,275 | |
| Ozempic Semaglutide | Brand | 14 | $14,095 | |
| Tradjenta Linagliptin | Brand | 12 | $13,444 | |
| Farxiga Dapagliflozin Propanediol | Brand | 18 | $12,770 |
The 10 drugs with the highest cost, of 181 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Records
6 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Family Medicine in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.